Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biocon Ltd. Capital/Financing Update 2023

Dec 13, 2023

61176_rns_2023-12-13_ca2b27ff-19cf-4c15-92b5-bf61e51f906f.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [132 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/132

December 13, 2023

BIO/SECL/AJ/2023-24/132
December 13, 2023
www.biocon.com
To,
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,Mumbai – 400 001
To,
The Manager
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Code – 532523 Scrip Symbol - BIOCON

Subject: Intimation under Regulation 30 of SEBI Listing Regulations.

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that Bicara Therapeutics Inc. (“Bicara”), an associate company of Biocon Limited, has on December 12, 2023, completed its US$165 Million Series C financing. The proceeds of the funding shall be used to support the continued advancement of Bicara’s lead product candidate, BCA101, a first-in-class bifunctional EGFR/TGF-β inhibitor that is currently in clinical development for multiple cancer types. The media release made by Bicara in this regard can be accessed at https://www.bicara.com/bicara-therapeutics-announcesoversubscribed-165-million-series-c-financing/.

Consequent to this infusion of Series C funding and post allotment of shares by Bicara, the Company’s shareholding in Bicara on fully diluted basis will fall below 20% and thereby, Bicara will cease to be an associate company of Biocon Limited.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2023.12.13 16:44:24 +05'30' _______

Mayank Verma

Company Secretary and Compliance Officer Membership No.: ACS 18776